Eric Ankerud has more than 25 years of product approval experience covering a wide range of pharmaceuticals, medical devices, and biologics. He joined Ocular Therapeutix in 2007, also serving as Executive Vice President, Clinical, Regulatory and Quality at a sister company Augmenix from 2008 until April 2014. Previously, Mr. Ankerud was the Vice President, Clinical, Regulatory and Quality of Confluent Surgical, Inc., and prior to this, held senior executive positions at Boston Scientific Corporation, Summit Technology, Inc., and Bausch + Lomb. He has also held senior management roles within C.R. Bard and its Surgical Products Group. Mr. Ankerud received a B.A. degree with highest honors in economics from St. Lawrence University and a J.D. degree from the Faculty of Law and Jurisprudence, State University of New York at Buffalo.